ABSTRACT Introduction. After parathyroidectomy for sporadic primary hyperparathyroidism (PHPT), overall rates of persistence/recurrence are extremely low. A marker of increased risk for persistence/recurrence is needed. We hypothesized that final intraoperative parathyroid hormone (FioPTH) C40 pg/mL is indicative of increased risk for disease persistence/recurrence, and can be used to selectively determine the degree of follow-up. Method. A retrospective review of PHPT patients undergoing parathyroidectomy with ioPTH monitoring was performed. An ioPTH decline of 50 % was the only criteria for operation termination. Patients were grouped based on FioPTH of \40, 40-59, and [60 pg/mL. Results. Between 2001 and 2012, 1,371 patients were included. Mean age was 61 ± 0.4 years, and 78°% were female. Overall persistence rate was 1.4°%, with a 2.9°% recurrence rate. Overall, 976 (71°%) patients had FioPTH \ 40, 228 (16.6°%) had FioPTH 40-59, and 167 (12.2°%) had FioPTH C60. Mean follow-up was 21 ± 0.6 months. Patients with FioPTH \40 were younger, with lower preoperative serum calcium, PTH, and creatinine (all p B 0.001). Patients with FioPTH \40 had the lowest persistence rate (0.2 %) versus patients with FioPTH 40-59 (3.5 %) or FioPTH C60 (5.4 %; p \ 0.001). Recurrence rate was also lowest in patients with FioPTH \40 (1.3 vs. 5.9 vs. 8.2 %, respectively; p \ 0.001). Disease-free status was greatest in patients with FioPTH \40 at 2 years (98.5 vs. 96.8 vs. 90.5 %, respectively) and 5 years (95.7 vs. 72.3 vs. 74.8 %, respectively; p \ 0.01). Conclusions. Patients with FioPTH \ 40 pg/mL had lower rates of persistence and recurrence, than patients with FioPTH 40-59, or C60. Differences became more apparent after 2 years of follow-up. Patients with FioPTH C40 pg/mL warrant close and prolonged follow-up.
Recurrence rate was also lowest in patients with FioPTH \40 (1.3 vs. 5.9 vs. 8.2 %, respectively; p \ 0.001). Disease-free status was greatest in patients with FioPTH \40 at 2 years (98.5 vs. 96.8 vs. 90.5 %, respectively) and 5 years (95.7 vs. 72.3 vs. 74.8 %, respectively; p \ 0.01). Conclusions. Patients with FioPTH \ 40 pg/mL had lower rates of persistence and recurrence, than patients with FioPTH 40-59, or C60. Differences became more apparent after 2 years of follow-up. Patients with FioPTH C40 pg/mL warrant close and prolonged follow-up.
Primary hyperparathyroidism (PHPT) is a common endocrinopathy and is only cured with surgical excision of the offending parathyroid gland(s). 1 With the advent of preoperative parathyroid localization studies, the use of intraoperative parathyroid hormone (ioPTH) monitoring, and radioguided parathyroidectomy (RPG), the surgical management of PHPT has largely moved to minimally invasive parathyroidectomy. [2] [3] [4] While preoperative imaging provides the surgeon with information regarding where to start the operation, RPG can provide immediate confirmation of parathyroid tissue resection, and ioPTH provides information regarding residual hyperfunctioning parathyroid tissue. 5 Protocols regarding timing of ioPTH draws and criteria to indicate termination of the operation vary slightly from institution to institution; however, most focus on a decline of 50 % or greater from baseline after the excision of the diseased gland(s), and most require multiple post-excision values of ioPTH to be sent. [6] [7] [8] [9] Additional stipulations required by some authors include falling into normal range for PTH within the assay-specific criteria. [10] [11] [12] Mild increases in ioPTH values (rebounding), even after initial decline criteria have been met, may also be indicative of additional hyperfunctioning glands. 13 Nearly all of these nuances regarding interpretation of ioPTH values focus on directly altering what is done in the operating room to minimize the risk of persistent disease. However, as the rate of disease persistence is generally \5 % regardless of the specific protocol used, might some of these subtleties be better markers of which patients are more likely to persist or recur, and therefore require closer and possibly more frequent follow-up?
Heller and Blumberg initially evaluated final ioPTH (FioPTH) levels with regard to persistent elevation of parathyroid hormone after surgery and risk of disease persistence.
14 These conclusions were based on a small sample size with a median follow-up of only 5 months, and stratified patients based on FioPTH values leading up to 40 pg/mL, with all patients with a FioPTH C40 pg/mL grouped together. The conclusions from this study were not widely adapted as the FioPTH C40 group included all patients who did not fall into a normal range of PTH values. We sought to further explore the concept of FioPTH value as a prognostic tool after parathyroid surgery, with stratification of patients with elevated FioPTH values which fell into normal range and those that did not. We hypothesized that an FioPTH of 40-59 pg/mL, as well as an FioPTH of C60 pg/mL, were markers of increased risk of disease persistence and recurrence.
METHODS
After approval by the Institutional Review Board, a retrospective review of a prospective parathyroid surgery database at an academic endocrine surgery practice was performed. Patients with a diagnosis of PHPT undergoing initial operative management were included. Patients with positive family history for PHPT, previous parathyroid surgery, concomitant thyroid surgery, or less than 6 months follow-up were excluded.
Unilateral exploration was performed if preoperative imaging studies, upon review by the surgeon, suggested a single adenoma. Bilateral neck exploration was performed when patients did not localize on preoperative imaging, had discordant imaging results, or on cases with less than 50 % ioPTH decline after the first adenoma resection. Blood samples for ioPTH monitoring were drawn from a peripheral IV after induction but before incision to establish a baseline level, and again at 5, 10, and 15 min following the excision of the enlarged gland. If the fifth minute post-excisional sample value was above the baseline level it would be considered as the baseline and two successive blood samples were drawn in 5-min intervals. 9 Additional samples were drawn at the discretion of the surgeon. Internal jugular vein sampling was reserved for patients with no reliable peripheral access. A decline of more than 50 % from the baseline at any time points described above signified adequate resection and prompted termination of the operation. 9 Patients were divided into three groups based on their FioPTH levels: \40 pg/mL, 40-59 pg/mL, and 60 pg/mL or higher. Serum PTH and calcium levels were routinely checked at the time of postoperative visit 1-2 weeks after surgery, and again at 6 months following surgery.
Disease persistence was defined as hypercalcemia ([10.2 mg/dL) occurring within 6 months of surgery. Recurrence was hypercalcemia occurring beyond 6 months postoperatively. Normocalcemia (B10.2 mg/dL) at 6-month follow-up defined 'cured'. A PTH of 60 pg/mL was considered as the upper limit of normal serum PTH range to account for the various reference ranges for different laboratory assays. 7 Statistical analysis was performed using IBM SPSS Statistics, version 21 (IBM Corporation, Armonk, NY, USA). Analysis of variance (ANOVA) and the KruskalWallis test were used to compare continuous variables. Categorical variables were compared using Chi square. The number of patients needed to treat (NNT) in order to prevent one disease persistence or recurrence were calculated to determine if FioPTH should alter operative management on the day of surgery. Estimated disease-free duration analysis was determined using Kaplan-Meier curves, and compared using Mantel-Cox log-rank. A p value B 0.05 was deemed significant. Results are expressed as mean ± standard error of the mean, unless otherwise stated.
RESULTS
Overall, 1,371 patients met the inclusion criteria between March 2001 and December 2012; 1,068 (77.9 %) patients were female and mean age was 61 ± 0.4 years. During this time, a majority of patients (66.4 %) were managed with a unilateral exploration. The most common finding at the time of surgery was single adenoma (77.6 %), followed by hyperplasia (12 %) and double adenoma (10.4 %). The overall cure rate was 98.6 %. During a mean follow-up of 21 ± 0.6 months, 39 patients (2.9 %) experienced disease recurrence.
Overall, 976 (71.2 %) patients had an FioPTH level \40, 228 (16.6 %) between 40 and 59, and 167 (12.2 %) had an FioPTH level C60 (Table 1) . Sex distribution was similar among groups (p = 0.15). Patients with an FioPTH of 40-59 and C60 were older than patients with an FioPTH \40, and had higher preoperative serum calcium, PTH and creatinine levels (all p \ 0.001). Preoperative vitamin D level was similar among groups (p = 0.36).
Rates of bilateral exploration were similar regardless of FioPTH grouping (p = 0.24; Table 2 ). Overall, 18.8 % of the study cohort had additional ioPTH samples sent after 15 min post-excision. Patients with higher FioPTH had additional ioPTH samples sent during parathyroidectomy (p \ 0.001). Serum calcium levels at the time of postoperative visit were equivalent (p = 0.14); however, serum postoperative PTH values were notably higher in patients with higher FioPTH (p \ 0.001). This trend continued through to the last measured PTH in follow-up (p \ 0.001).
The highest cure rate following parathyroidectomy (99.8 %) was in patients with FioPTH \40 (p \ 0.001; Table 3 ). After 21 ± 0.6 months of follow-up, 1.3 % of patients with FioPTH \40 (n = 13) experienced disease recurrence, which was the lowest recurrence rate (p \ 0.001).
The cure rate in FioPTH 40-59 was 96.5 %. 22 ± 0.7 months of follow-up revealed recurrent hyperparathyroidism in 5.9 % (n = 13) of patients with FioPTH 40-59. About 95 % of patients with FioPTH C60 were cured after parathyroidectomy. Recurrence rate was 8.2 % (n = 13) after 20 ± 1.7 months of follow-up in patients with FioPTH C60.
For patients with FioPTH of 40-59, more extensive parathyroidectomy would be performed on 30 patients to prevent one persistence, or 22 patients to prevent one recurrence. In those patients with an FioPTH C60, the NNT to prevent one persistence was 19 patients, and 15 patients for recurrence.
Estimated disease-free rate for the overall study population at 1 year after parathyroidectomy was 98.6 %. The disease-free rates at 2 and 5 years after parathyroidectomy were 97.2 and 89.6 %. The difference in disease-free status between FioPTH \40 and FioPTH C40 was minimal at 1-year follow-up, but became more marked after 2 and 5 years of follow-up (Fig. 1) . The highest disease-free rates were detected in patients with FioPTH \40 (99.5 % at 1 year, 98.5 % at 2 years, 95.7 % at 5 years; p \ 0.001; Postoperative laboratories (mean ± SEM) Calcium (mg/dL) 9.3 ± 0.02 9.4 ± 0.04 9.4 ± 0.05 0.14 PTH (pg/mL) 41 ± 1 5 5 ± 2 7 1 ± 4 \0.001
Statistically significant values are given in bold Data expressed as N (%) unless otherwise specified
FioPTH final intraoperative parathyroid hormone, PTH parathyroid hormone, SEM standard error of the mean Table 4 ). Disease-free rates were similar in patients with FioPTH 40-59 and FioPTH C 60.
DISCUSSION
Current practice in parathyroid surgery regarding the use of ioPTH monitoring focuses the direct influence of ioPTH monitoring on intraoperative decision making. 5, 7 However, ioPTH values can also provide the surgeon and clinician with valuable information regarding patient prognosis and the need for further follow-up. The data presented here demonstrate how FioPTH can be a marker for increased risk for disease persistence and recurrence in patients undergoing parathyroidectomy for PHPT. Patients with an FioPTH C40 experienced higher rates of disease persistence and recurrence after parathyroidectomy. This high rate of persistence and recurrence occurred even if the FioPTH fell within normal range but was still 40 or higher. Most patients (72 %) experienced a drop in FioPTH to less than 40 pg/mL, but a disproportionately high number of patients with FioPTH C40 accounted for all cases of persistent (69 %) and recurrent (89 %) disease.
In the initial study by Heller and Blumberg, 194 patients were stratified by FioPTH in 10 pg/mL intervals, up to 40 pg/mL, with all patients with an FioPTH C40 pg/mL making up the final comparison group.
14 Patients with FioPTH C40 were more likely to have both persistent PTH elevation as well as persistent PHPT, similar to our findings. However, due to the limited follow-up, no conclusions could be made regarding disease recurrence, and even disease persistence may be higher than reported as only 80 % of patients had 3 months follow-up. As this study was based on FioPTH levels drawn at 20 min postexcision, they may represent slightly different PTH kinetics than those of this study, as our protocol generally stopped at the 15 min value.
Although Heller and Blumberg first proposed the use of FioPTH, Wharry et al. further explored the concept in a larger group of patients with a longer follow-up. 14, 15 In an effort to determine the need for FioPTH to fall into a normal PTH range, patients were categorized as upper 
Statistically significant values are given in bold Data expressed as mean ± SEM unless otherwise specified normal FioPTH (41-65 pg/mL) or elevated FioPTH ([65 pg/mL). They evaluated 1,108 individuals with a mean follow-up of 1.8 years, and found that patients with upper normal FioPTH had similar rates of persistence, but higher recurrence rates compared with those with FioPTH B40 g/mL. 15 However, Wharry et al. found that only patients with elevated FioPTH ([65 pg/mL) experienced higher rates of disease persistence and recurrence. This is in contrast to the results presented here, which demonstrated a stepwise increase in both disease persistence and recurrence in patients with FioPTH 40-59 and C60 when compared with patients with FioPTH \40. Our findings are based on a larger patient population, but with similar duration of follow-up.
Previous authors suggested that an ioPTH decline of C50 %, and falling into normal limit, is the optimal method of ioPTH monitoring. [10] [11] [12] 16 Although this describes a more restricted criterion for ioPTH monitoring, studies have not assessed the number of patients who would undergo unnecessary additional surgery by practicing this criterion. In the present study, the number of patients who would undergo more extensive parathyroid resection if FioPTH dictated intraoperative decision making is addressed (Table 3) . More extensive parathyroid resection in patients with PHPT has been previously demonstrated to result in increased rates of postoperative transient hypocalcemia and permanent hypoparathyroidism. 17 This must be balanced with the risks of disease persistence and recurrence. Additional data suggest normalization of PTH in the postoperative period results in a more rapid improvement in symptomology. 18 Exposing a considerable number of patients to bilateral exploration to minimize disease persistence and/or recurrence may not be a proper strategy to manage PHPT. Rather, a more effective strategy involves identifying those patients as individuals in need of close follow-up to ensure timely diagnosis and intervention of disease persistence and/or recurrence. 19 Rates of disease persistence and recurrence were comparable between FioPTH 40-59 and FioPTH C60. In contrast to previous published studies that recommend an ioPTH decline to normal range to minimize disease persistence and recurrence, the data presented above suggest that an FioPTH decline into normal range may not reduce the risk of persistence and/or recurrence unless it drops to \40 pg/mL. [10] [11] [12] In addition, the noted differences between disease-free intervals did not become evident until approximately 2 years of follow-up, with continued divergence at 5 years. This supports ongoing, active surveillance in these patients who are at increased risk, well beyond the 6-month mark often used by many surgeons.
Patients with FioPTH \40 were younger and had lower preoperative serum calcium, PTH and creatinine levels, and postoperative PTH level. Conversely, patients with higher FioPTH were notably older, and with higher serum creatinine levels. Previous studies discussed the controversial aspects of age and glomerular filtration rate (GFR) and their respective influences on ioPTH decline in patients with PHPT. 20, 21 Although FioPTH decline to\40 pg/mL may be multifactorial, younger age and more efficient renal function may play a role. The kinetics of ioPTH, as well as PTH level measured at the postoperative visit, are also influenced by preoperative vitamin D levels. 22, 23 Patients with vitamin D deficiency have less of a decline in ioPTH at 5 min postexcision, and higher postoperative PTH level. Vitamin D deficiency may result in persistent PTH elevation with normocalcemia after parathyroidectomy, which may be prevented or resolved by vitamin D supplementation. 24, 25 Within our study population, vitamin D levels did not differ, based on the FioPTH group suggesting vitamin D deficiency is not the sole contributor to FioPTH elevation.
This study was a retrospective review of a prospective database, and thus has inherent limitations. While a majority of patients had FioPTH levels representing 15 min post-excision values, nearly 20 % had FioPTH drawn beyond that, or after additional glands were excised. As the initial description by Heller was using a 20 min sample, addition decline may occur if 20 min values are measured almost 20 % of patients had their FioPTH taken after 15 min following gland excision. Comparison of their FioPTH level with the FioPTH of the rest of the study population may not be accurate. About 37 % of the study population did not have preoperative vitamin D evaluation, which may affect this comparison across FioPTH levels. Disease-free survival was estimated at the end of the second and fifth follow-up years, which may have some discrepancies with the actual disease-free rates if all patients had follow-up through those timepoints.
CONCLUSIONS
After parathyroidectomy for PHPT, patients with FioPTH C40 pg/ml have a greater risk of disease persistence and/or recurrence than patients with FioPTH \40 pg/mL. Patients with an FioPTH C40 pg/mL experienced lower disease-free status after 2 and 5 years of follow-up. These findings do not necessarily support more extensive parathyroidectomy due to the high number of patients needed to treat in order to prevent a single episode of persistence and/or recurrence. Instead, we propose FioPTH as a marker of patients at increased risk of disease persistence and/or recurrence, which justifies closer, and more frequent, follow-up.
